Abstract
AbstractIn this short report, we demonstrate that liposomes bearing the Lewis X trisaccharide on the surface (“Awesosomes”) efficiently target human dendritic cells. We chose a glycolipid with Lewis X trisaccharide headgroup to facilitate the targeted liposome uptake via the DC-SIGN internalization pathway. While no uptake of Awesosomes was detected with wild-type human HEK293 cells, HEK293 cells transfected with human DC-SIGN internalized Awesosomes extensively. In samples of human blood-derived leukocytes, the extent of uptake of Awesosomes correlated with the expression of DC-SIGN, which is a dendritic cells marker. There was a marked difference in the uptake of Awesosomes and plain liposomes by DC-SIGN expressing dendritic cells. There was no difference in uptake of Awesosomes and plain liposomes by wt HEK293 cells or macrophages. These results indicate that Lewis X trisaccharide can “sweet-talk” dendritic cells into internalizing a delivery vehicle, and that Awesosomes are promising as “magic bullets” for specific delivery of drugs, antigens, or immunostimulatory molecules to human dendritic cells without influencing other cell types.
Highlights
Dendritic cells (DCs) are the most powerful antigen presenting cells
We demonstrate that liposomes bearing the Lewis X trisaccharide on the surface (“Awesosomes”) efficiently target human dendritic cells
We chose a glycolipid with Lewis X trisaccharide headgroup to facilitate the targeted liposome uptake via the DC-SIGN internalization pathway
Summary
Dendritic cells (DCs) are the most powerful antigen presenting cells. They are extremely potent in priming naïve T-cells (and have been designated the “nature’s adjuvants” [Steinman, 2007], and in inducing cytotoxic immune responses (CTL). DCs are capable of crosspresentation, the induction of a cytotoxic cell response against exogenously acquired antigen [Bevan, 1976]. This mode of CTLs induction against an exogenous antigen has been described only relatively recently and is extremely important for developing vaccines against certain pathogens including malaria, HIV, and TB [Winau, 2006], and against tumor cells. Targeted delivery of immunostimulants should decrease the likelihood of mounting a generalized inflammatory response; current adjuvants elicit a generalized inflammatory response, often leading to a number of side effects like swelling
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.